A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

Glembatumumab vedotin (CDX-011, GV) is a fully human Immunoglobulin G2 monoclonal antibody directed against glycoprotein NMB coupled via a peptide linker to monomethyl auristatin E (MMAE), a potent cytotoxic microtubule inhibitor. This phase II study evaluated the overall response rate and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasanov, Merve, Rioth, Matthew J., Kendra, Kari, Hernandez-Aya, Leonel, Joseph, Richard W., Williamson, Stephen, Chandra, Sunandana, Shirai, Keisuke, Turner, Christopher D., Lewis, Karl, Crowley, Elizabeth, Moscow, Jeffrey, Carter, Brett, Patel, Sapna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465139/
https://www.ncbi.nlm.nih.gov/pubmed/32823698
http://dx.doi.org/10.3390/cancers12082270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465139/
https://www.ncbi.nlm.nih.gov/pubmed/32823698
http://dx.doi.org/10.3390/cancers12082270

Ejemplares similares